Trial Profile
SUN4936c clinical trial phase 2 An exploratory clinical trial of safety and efficacy of SUN4936c for preventing contrast-induced nephropathy in patients with renal dysfunction who are planned to receive iodine contrast
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2021
Price :
$35
*
At a glance
- Drugs Carperitide (Primary)
- Indications Kidney disorders
- Focus Therapeutic Use
- 05 Mar 2021 Planned number of patients changed from 240 to 65.
- 07 Sep 2018 New trial record